MC1992A1 - Derives de fluorocytidine - Google Patents

Derives de fluorocytidine

Info

Publication number
MC1992A1
MC1992A1 MC882015A MC2015A MC1992A1 MC 1992 A1 MC1992 A1 MC 1992A1 MC 882015 A MC882015 A MC 882015A MC 2015 A MC2015 A MC 2015A MC 1992 A1 MC1992 A1 MC 1992A1
Authority
MC
Monaco
Prior art keywords
fluorocytidine derivatives
fluorocytidine
derivatives
Prior art date
Application number
MC882015A
Other languages
English (en)
Inventor
Fujiu Morio
Ishitsuka Hideo
Miwa Masanori
Umeda Isao
Yokose Kazuteru
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MC1992A1 publication Critical patent/MC1992A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
MC882015A 1987-11-17 1988-11-14 Derives de fluorocytidine MC1992A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP87116926 1987-11-17

Publications (1)

Publication Number Publication Date
MC1992A1 true MC1992A1 (fr) 1989-11-30

Family

ID=8197450

Family Applications (1)

Application Number Title Priority Date Filing Date
MC882015A MC1992A1 (fr) 1987-11-17 1988-11-14 Derives de fluorocytidine

Country Status (35)

Country Link
US (1) US4966891A (fr)
EP (1) EP0316704B1 (fr)
JP (1) JPH0678350B2 (fr)
KR (1) KR970000241B1 (fr)
CN (1) CN1022688C (fr)
AR (1) AR247217A1 (fr)
AT (1) ATE124951T1 (fr)
AU (1) AU619220B2 (fr)
CA (1) CA1327358C (fr)
CS (1) CS274486B2 (fr)
DE (2) DE3854148D1 (fr)
DK (1) DK170893B1 (fr)
DZ (1) DZ1270A1 (fr)
ES (1) ES2074429T3 (fr)
FI (1) FI89804C (fr)
GR (1) GR3017686T3 (fr)
HK (1) HK1003114A1 (fr)
HU (1) HU199866B (fr)
IE (1) IE883430L (fr)
IL (1) IL88363A0 (fr)
IS (1) IS1895B (fr)
LT (1) LT2185B (fr)
LU (1) LU90769I2 (fr)
LV (1) LV5624A3 (fr)
MC (1) MC1992A1 (fr)
MX (1) MX173347B (fr)
NL (1) NL300045I2 (fr)
NO (2) NO171167C (fr)
NZ (1) NZ226923A (fr)
PH (1) PH25641A (fr)
PT (1) PT89009B (fr)
SU (1) SU1736342A3 (fr)
UA (1) UA19333A (fr)
YU (1) YU47122B (fr)
ZA (1) ZA888428B (fr)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258360B1 (en) * 1989-05-04 2001-07-10 Igen International, Inc. Prodrugs activated by targeted catalytic proteins
US5527782A (en) * 1990-03-13 1996-06-18 Acic (Canada) Inc. 5-halo-2,3'-O-cyclocytidines
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
TW254946B (fr) * 1992-12-18 1995-08-21 Hoffmann La Roche
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
EP0882734B1 (fr) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag Dérivés de 5'-déoxy-cytidine
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20010051348A1 (en) * 2000-01-28 2001-12-13 Lee Chee Wee Novel ligands and methods for preparing same
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
EP2316468A1 (fr) 2002-02-22 2011-05-04 Shire LLC Système de distribution et méthodes de protection et d'administration de dextroamphetamine
US6774758B2 (en) * 2002-09-11 2004-08-10 Kalyan P. Gokhale Low harmonic rectifier circuit
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
AU2003233586A1 (en) * 2003-05-20 2005-01-21 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising capecitabine and a liposomal platinum complex
KR20080046752A (ko) * 2003-12-22 2008-05-27 에프. 호프만-라 로슈 아게 플루오로시티딘 유도체에 대한 방법
RU2392275C2 (ru) * 2004-02-18 2010-06-20 Астразенека Аб Бензамидные производные и их применение в качестве активирующих глюкокиназу агентов
CA2554686A1 (fr) * 2004-02-18 2005-09-01 Astrazeneca Ab Composes
CN100383128C (zh) * 2004-02-23 2008-04-23 上海迪赛诺医药发展有限公司 N4－氧羰基胞嘧啶衍生物及制备方法与应用
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
KR101061850B1 (ko) 2004-09-08 2011-09-02 삼성전자주식회사 박막 트랜지스터 표시판 및 그 제조방법
GB0421294D0 (en) * 2004-09-24 2004-10-27 Angiogene Pharm Ltd Bioreductively-activated prodrugs
BRPI0516595A (pt) 2004-10-16 2008-09-23 Astrazeneca Ab processo para fabricar um composto, e, composto
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
CN102886045A (zh) 2005-02-03 2013-01-23 综合医院公司 治疗吉非替尼耐药性癌症的方法
NO322682B1 (no) * 2005-03-18 2006-11-27 Clavis Pharma Asa Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
AU2006228581A1 (en) * 2005-04-01 2006-10-05 F. Hoffmann-La Roche Ag Method for administration of capecitabine
WO2006125958A1 (fr) * 2005-05-24 2006-11-30 Astrazeneca Ab Derives d’imidazol[4,5b]pyridine/pyrazine et purine substitues en 2-phenyl en tant que modulateurs de la glucokinase
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
US20080234273A1 (en) * 2005-07-09 2008-09-25 Mckerrecher Darren Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes
US20110053910A1 (en) * 2005-07-09 2011-03-03 Mckerrecher Darren 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
KR101346902B1 (ko) 2005-07-09 2014-01-02 아스트라제네카 아베 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한헤테로아릴 벤즈아미드 유도체
CN100569790C (zh) * 2005-07-15 2009-12-16 上海奥锐特国际贸易有限公司 合成n4-酰基-5＇-脱氧-5-氟胞苷衍生物的方法
JP2009501734A (ja) * 2005-07-21 2009-01-22 ヌボ・リサーチ・インコーポレイテッド 癌の治療方法
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
EP1942937A1 (fr) 2005-11-04 2008-07-16 Wyeth Combinaisons antineoplasiques a base d'inhibiteur de mtop, d'herceptine et/ou de khi-272
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
TW200825063A (en) 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
TW200825060A (en) 2006-10-26 2008-06-16 Astrazeneca Ab Chemical compounds
CN100425617C (zh) * 2006-10-31 2008-10-15 浙江海正药业股份有限公司 一种含氟嘧啶类化合物烷氧羰酰化的方法
AU2007336016A1 (en) 2006-12-21 2008-06-26 Astrazeneca Ab Novel crystalline compound useful as GLK activator
ITMI20070435A1 (it) 2007-03-05 2008-09-06 Innovate Biotechnology Srl 2',3'-di-o-acil-5-fluoronucleosidi
MX2009011255A (es) * 2007-04-20 2009-11-23 Reddys Lab Ltd Dr Proceso para preparar capecitabina.
WO2008145403A1 (fr) * 2007-06-01 2008-12-04 Synthon B.V. Procédés se rapportant à la fabrication de la capécitabine
US8741858B2 (en) 2007-09-21 2014-06-03 Zhongxu Ren Oligomer-nucleoside phosphate conjugates
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US20090209754A1 (en) * 2008-01-03 2009-08-20 Macdonald Peter Lindsay Process for the preparation of capecitabine
PL2310011T3 (pl) 2008-06-17 2013-12-31 Wyeth Llc Kombinacje przeciwnowotworowe zawierające HKI-272 i vinorelbine
SG10202102855RA (en) * 2008-08-04 2021-05-28 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
EA201100097A1 (ru) 2008-08-04 2011-10-31 Астразенека Аб Производные пиразоло[3,4]пиримидин-4-ила и их применения для лечения диабета и ожирения
EP2370414A4 (fr) * 2008-12-02 2012-11-14 Reddys Lab Ltd Dr Préparation de capécitabine
US8603999B2 (en) 2008-12-05 2013-12-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
CN101787066B (zh) * 2009-01-23 2013-07-31 高峰 阿糖胞苷衍生物及其在抗癌抗肿瘤中的用途
GB0902434D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
GB0902406D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
MX356593B (es) 2009-04-06 2018-06-05 Wyeth Llc Régimen de tratamiento que utiliza neratinib para cáncer de mama.
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
AR076221A1 (es) * 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
CN101875680B (zh) * 2009-04-28 2012-07-25 上海信旗医药科技有限公司 一种核苷类化合物及其制备方法和应用
JP2012533618A (ja) * 2009-07-23 2012-12-27 サイノファーム タイワン リミテッド フルオロシチジン誘導体の製造プロセス
TR201816180T4 (tr) 2010-03-12 2018-11-21 Genzyme Corp Meme kanserini tedavi etmek için kombinasyonlu tedavi.
EP3501550A1 (fr) 2012-04-02 2019-06-26 Moderna Therapeutics, Inc. Polynucléotides modifiés pour la production de protéines associées à une maladie humaine
CN104411338A (zh) 2012-04-02 2015-03-11 现代治疗公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
CN104640858B (zh) 2012-09-26 2018-11-06 霍夫曼-拉罗奇有限公司 环醚吡唑-4-基-杂环基-甲酰胺化合物及使用方法
CA2890359A1 (fr) 2012-11-07 2014-05-15 Zucai SUO Analogues arylamides substitues de gemcitabine
EP2971033B8 (fr) 2013-03-15 2019-07-10 ModernaTX, Inc. Procédés de fabrication pour la production de transcrits d'arn
EP2968382B1 (fr) 2013-03-15 2018-03-07 Nucorion Pharmaceuticals, Inc. Analogues d'amide bicyclique de gemcitabine substitués et méthodes de traitement à l'aide de ceux-ci
WO2015034928A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides chimériques
EP3041938A1 (fr) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Polynucléotides circulaires
CN103450301B (zh) * 2013-09-09 2015-09-09 南通大学 法尼基硫代水杨酸-核苷缀合物、其制备方法及其医药用途
EP3052521A1 (fr) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucléotides codant pour un récepteur de lipoprotéines de faible densité
WO2018002739A1 (fr) * 2016-06-28 2018-01-04 Cellix Bio Private Limited Compositions et méthodes pour le traitement du cancer
US11034667B2 (en) 2017-01-09 2021-06-15 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
JP7173613B2 (ja) 2017-04-26 2022-11-16 カールマン，トーマス，アイ． 多標的ヌクレオシド誘導体
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
CA3087565A1 (fr) 2018-01-09 2019-07-18 Shuttle Pharmaceuticals, Inc. Inhibiteurs selectifs d'histone deacetylase pour le traitement d'une maladie humaine
WO2019143860A1 (fr) * 2018-01-19 2019-07-25 Nucorion Pharmaceuticals, Inc. Composés de 5-fluorouracile
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
SG11202100411TA (en) * 2018-08-03 2021-02-25 Cellix Bio Private Ltd Compositions and methods for the treatment of cancer
CN109651467A (zh) * 2019-01-15 2019-04-19 齐鲁天和惠世制药有限公司 一种卡培他滨杂质及其制备方法
WO2021216427A1 (fr) 2020-04-21 2021-10-28 Ligand Pharmaceuticals, Inc. Composés de promédicaments nucléotidiques
CN116710079A (zh) 2020-07-24 2023-09-05 斯特兰德生物科技公司 包含经修饰的核苷酸的脂质纳米颗粒
WO2022150712A1 (fr) 2021-01-08 2022-07-14 Strand Therapeutics, Inc. Constructions d'expression et leurs utilisations
WO2023212618A1 (fr) 2022-04-26 2023-11-02 Strand Therapeutics Inc. Nanoparticules lipidiques comprenant un réplicon d'encéphalite équine du vénézuela (vee) et leurs utilisations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3404144A (en) * 1965-12-23 1968-10-01 Research Corp 1-beta-d-arabinofuranosyl-5-fluorocytosine compounds
GB1379410A (en) * 1971-06-08 1975-01-02 Upjohn Co 1-beta-d-arabino-furanosyl-n4-alpha-aminoacylcytosines
JPS52153977A (en) * 1976-06-11 1977-12-21 Daikin Ind Ltd Synthesis of 5-fluorouracil and its derivatives
US4071680A (en) * 1976-12-20 1978-01-31 Hoffmann-La Roche Inc. 5'-Deoxy-5-fluoropyrimidine nucleosides
CH633810A5 (en) * 1978-01-01 1982-12-31 Hoffmann La Roche Novel nucleosides and process for their preparation
FR2528311B1 (fr) * 1982-06-14 1985-06-14 Synthelabo Compositions pharmaceutiques a base de xylosides et lyxosides de bases puriques et pyrimidiques
JPS61112093A (ja) * 1984-11-05 1986-05-30 Wakunaga Seiyaku Kk ヌクレオチド誘導体

Also Published As

Publication number Publication date
SU1736342A3 (ru) 1992-05-23
FI89804C (fi) 1993-11-25
KR970000241B1 (ko) 1997-01-08
DE10199027I1 (de) 2001-08-02
LV5624A3 (lv) 1994-05-10
GR3017686T3 (en) 1996-01-31
AU619220B2 (en) 1992-01-23
NO2001013I2 (no) 2006-05-01
DK170893B1 (da) 1996-03-04
AU2516888A (en) 1989-05-25
IE883430L (en) 1989-05-17
CN1022688C (zh) 1993-11-10
DZ1270A1 (fr) 2004-09-13
PT89009A (pt) 1988-12-01
PH25641A (en) 1991-08-21
CS747588A2 (en) 1990-09-12
JPH0678350B2 (ja) 1994-10-05
NO885106L (no) 1989-05-18
HUT48267A (en) 1989-05-29
HK1003114A1 (en) 1998-10-09
CN1033183A (zh) 1989-05-31
AR247217A1 (es) 1994-11-30
NO885106D0 (no) 1988-11-16
MX173347B (es) 1994-01-03
HU199866B (en) 1990-03-28
EP0316704A2 (fr) 1989-05-24
FI885329A0 (fi) 1988-11-17
NL300045I2 (nl) 2002-01-02
IL88363A0 (en) 1989-06-30
FI885329A (fi) 1989-05-18
DE3854148D1 (de) 1995-08-17
IS1895B (is) 2003-10-20
US4966891A (en) 1990-10-30
NZ226923A (en) 1990-10-26
JPH01153696A (ja) 1989-06-15
LT2185B (lt) 1993-10-15
ZA888428B (en) 1989-06-28
EP0316704A3 (en) 1990-11-22
PT89009B (pt) 1993-02-26
ATE124951T1 (de) 1995-07-15
NO171167C (no) 1993-02-03
CA1327358C (fr) 1994-03-01
FI89804B (fi) 1993-08-13
DK640388D0 (da) 1988-11-16
NO171167B (no) 1992-10-26
DE10199027I2 (de) 2002-01-31
UA19333A (uk) 1997-12-25
DK640388A (da) 1989-05-18
YU209188A (en) 1990-08-31
LU90769I2 (fr) 2001-07-02
YU47122B (sh) 1994-12-28
ES2074429T3 (es) 1995-09-16
IS3412A7 (is) 1989-05-18
CS274486B2 (en) 1991-04-11
NL300045I1 (nl) 2001-08-01
MX13836A (es) 1993-10-01
KR890008162A (ko) 1989-07-10
EP0316704B1 (fr) 1995-07-12

Similar Documents

Publication Publication Date Title
MC1992A1 (fr) Derives de fluorocytidine
DE3856154D1 (de) Adenosin-Derivate
MC1953A1 (fr) Derives de la benzopyrane
TR26815A (tr) Azolilmetil-sikropil türevleri
MC1921A1 (fr) Derives acyles
DK23489A (da) Nucleosidderivater
MC1879A1 (fr) Derives de la pyridazodiazepine
DK564088A (da) Nukleosidderivater
TR24894A (tr) N-FENILPIRAZOL TüREVLERI
DK507188D0 (da) Cholecalciferolderivater
FR2639044B1 (fr) Derives de la butynylamine
MC1970A1 (fr) Derives acyles
DK378088D0 (da) Alkenderivater
MC1916A1 (fr) Derives de propiolophenone
MC1984A1 (fr) Derives de la purine
BR8905292A (pt) Derivados de piranobenzoxadiazois
MC1934A1 (fr) Derives de pyrimidine
MC1920A1 (fr) Derives acyles
MC2000A1 (fr) Derives acyles
MC2108A1 (fr) Derives de quinoleine
DK271088D0 (da) Tienopyridinderivater
DK695788A (da) Naphtalenderivater
MC1952A1 (fr) Derives acyles
DK71488A (da) Dipenylethylen-derivater
DK733688A (da) Dioxazocinderivater